Retinal microvascular changes appear to be associated with development of disability in performing activities of daily living among older adults, and retinal signs may be useful in predicting outcomes among this population, according to a report published Online First by Archives of Ophthalmology. http://medicalxpress.com/news/2011-11-retinal-microvascular-disability-daily-older.html
“People with diabetes are 10 to 20 times more likely to go blind than someone without the condition, due to diabetic retinopathy. However, if this condition is detected early through an eye examination and treated, blindness can be prevented in 90% of cases” http://www.irishhealth.com/article.html?id=20014
A long-term study from Australia has claimed that there has been a significant reduction in the number of cases of retinopathy among young patients with type 1 diabetes who have had intensive glycaemic control therapy. http://www.diabetes.co.uk/news/2011/Oct/adolescents-with-diabetes-experiencing-decrease-in-retinopathy-95087803.html
A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage. http://www.medscape.com/viewarticle/752133
With more drugmakers outsourcing more trials to contract research organizations, few should be surprised that the CRO sector is generating investor interest. The attention-grabbing deal announced this week in which two private equity firms – Carlyle Group and Hellman & Friedman – agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development is…